Santen News The latest news for Santen Inc, U.S.A. http://www.santeninc.com Santen Announces FDA Orphan Drug Status for Sirolimus (DE-­‐109) Emeryville, CA (Nov 10, 2011) – Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), & Global Clinical Development and Medical Affairs at Santen today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for sirolimus (DE-­‐109) for the treatment of chronic/refractory anterior non-­‐infectious uveitis, non-­‐infectious intermediate uveitis, non-­‐infectious panuveitis, and non-­‐infectious uveitis affecting the posterior segment of the eye. http://www.santeninc.com/news/11-11_Santen_FDA ORPHAN STATUS.pdf Santen Announces EMA Orphan Drug Status For Sirolimus (DE-109) Emeryville, CA (Sept 8, 2011) Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced the European Commission (EC) has granted orphan drug status for sirolimus (DE‐109) for the treatment of chronic non‐infectious uveitis. http://www.santeninc.com/news/11-09_Orphan_Status_Alert.pdf Santen Inc. Builds Global Medical Affairs Team Emeryville, CA (July 12, 2011) Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. of Osaka, Japan, announced the addition of four new employees to the Global Clinical and Medical Affairs Group. http://www.santeninc.com/news/11-07_Santen_New_Hire_Release.pdf Santen announces Phase III Program Napa, CA (June 20, 2011) Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced the initiation of a global Phase III clinical study evaluating its investigational drug sirolimus (DE-109) for the treatment of non infectious posterior uveitis. http://www.santeninc.com/news/11-06_DE-109Phase_III_Final.pdf Santen Inc. Announces Relocation of U.S. Corporate Headquarters Napa, CA (April 11, 2011) Santen Inc., a wholly‐owned subsidiary of Santen Pharmaceutical Co., Ltd., Osaka, Japan, has announced that its U.S. corporate headquarters, currently located in Napa, California, will relocate to 2100 Powell in Emeryville, California in early July 2011. http://www.santeninc.com/news/11-04_EmeryvilleLocation.pdf